A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study).
Cristina MussiniEnrica RoncagliaVanni BorghiStefano RusconiSilvia NozzaAnna Maria CattelanDaniela SegalaPaolo BonfantiAntonio Di BiagioEnrico BarchiEmanuele Foca'Anna Degli AntoniStefano BonoraDaniela FrancisciSilvia LimontaAndrea AntinoriGabriella D'EttorreFranco MaggioloPublished in: PloS one (2019)
EUDRACT number: 2011-005973-21.
Keyphrases
- hiv positive
- antiretroviral therapy
- hiv infected patients
- hiv infected
- men who have sex with men
- human immunodeficiency virus
- induced apoptosis
- south africa
- cell cycle arrest
- study protocol
- clinical trial
- phase iii
- phase ii
- endoplasmic reticulum stress
- randomized controlled trial
- signaling pathway
- oxidative stress
- hepatitis c virus
- cell proliferation
- adverse drug